AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21134027 — intervention group
Group type: COMPARATOR
Intervention: RV outflow tract pacing
Number of subjects: 40
Study 19548930 — intervention group
Group type: EXPERIMENTAL
Intervention: Zurich protocol (n = 3 teeth/5 roots)
Number of subjects: 9
Study 19548930 — intervention group
Group type: EXPERIMENTAL
Intervention: Eastman Dental Institute (EDI) protocol (n = 4 teeth/4 roots)
Number of subjects: 9
Study 19548930 — intervention group
Group type: EXPERIMENTAL
Intervention: All microscopy techniques (SEM, LM, TEM) used on each root
Number of subjects: 9
Study 16842379 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin plus paclitaxel
Number of subjects: 160
Study 16842379 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin
Number of subjects: 160
Study 14636938 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual vacuum aspiration (MVA)
Number of subjects: 154
Study 14636938 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual vacuum aspiration (MVA) with contraceptive counseling
Number of subjects: 154
Study 14636938 — intervention group
Group type: COMPARATOR
Intervention: Sharp curettage
Number of subjects: 154
Study 11038410 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.5% CHO solution (8 ml (kg body mass (BM))‐1)
Number of subjects: 7
Study 11038410 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution (CON trial)
Number of subjects: 7
Study 8860111 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg/day)
Number of subjects: 20
Study 8860111 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg, three times a day for 3 days)
Number of subjects: 20
Study 2051556 — intervention group
Group type: EXPERIMENTAL
Intervention: Face mask
Number of subjects: 30
Study 2051556 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilated canopy
Number of subjects: 30
Study 2051556 — intervention group
Group type: COMPARATOR
Intervention: Mouthpiece/nose clip
Number of subjects: 30
Study 2051556 — intervention group
Group type: EXPERIMENTAL
Intervention: All systems
Number of subjects: 30
Study 6686774 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-pyridylcarbinol (Ronicol 300)
Number of subjects: 10
Study 31445316 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 supplementation (2.5 g/d for 45 days)
Number of subjects: 40
Study 31445316 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 supplementation
Number of subjects: 40
Study 31445316 — intervention group
Group type: COMPARATOR
Intervention: Control group (olive oil capsules)
Number of subjects: 40
Study 29168358 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined multi-strain and multi-species probiotics (Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus plantorum, Bifidobacterium animalis) with prebiotics (fructooligosaccharides and galactooligosaccharides)
Number of subjects: 110
Study 29168358 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probiotics)
Number of subjects: 110
Study 29168358 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined multi-strain and multi-species probiotics
Number of subjects: 110
Study 24939630 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-cervical double balloon catheter with extra-amniotic saline infusion (EASI)
Number of subjects: 160
Study 24939630 — intervention group
Group type: COMPARATOR
Intervention: Trans-cervical double balloon catheter without extra-amniotic saline infusion (Control)
Number of subjects: 160
Study 24101043 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel plus prednisone (C + P)
Number of subjects: 0
Study 24101043 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone plus prednisone (C)
Number of subjects: 0
Study 21767400 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate Day Fasting (ADF)
Number of subjects: 60
Study 21767400 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie Restriction (CR)
Number of subjects: 60
Study 21767400 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 60
Study 21767400 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 19499762 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive protocol (PG) including preoperative upper limb lymphscintigraphy (LS), principles for lymphedema risk minimization, and early management of identified lymphedema.
Number of subjects: 55
Study 19499762 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 55
Study 16719655 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory for bound combinations of features (colors or shapes) with simultaneous presentation
Number of subjects: 0
Study 16719655 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory for bound combinations of features (colors or shapes) with sequential presentation
Number of subjects: 0
Study 16719655 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory for feature combinations under demanding concurrent verbal tasks
Number of subjects: 0
Study 15305887 — intervention group
Group type: EXPERIMENTAL
Intervention: gliclazide MR 30-120 mg daily
Number of subjects: 845
Study 15305887 — intervention group
Group type: COMPARATOR
Intervention: glimepiride 1-6 mg daily
Number of subjects: 845
Study 11778352 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular physical activity
Number of subjects: 0
Study 11778352 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affect
Number of subjects: 0
Study 11778352 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative affect
Number of subjects: 0
Study 11778352 — intervention group
Group type: EXPERIMENTAL
Intervention: Older, married, and employed women
Number of subjects: 0
Study 11778352 — intervention group
Group type: EXPERIMENTAL
Intervention: Women perceiving high risk for breast cancer
Number of subjects: 0
Study 11778352 — intervention group
Group type: EXPERIMENTAL
Intervention: More educated women and those with higher perceived risk
Number of subjects: 0
Study 11778352 — intervention group
Group type: EXPERIMENTAL
Intervention: Married women
Number of subjects: 0
Study 10806834 — intervention group
Group type: EXPERIMENTAL
Intervention: aprotinin
Number of subjects: 20
Study 10806834 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 7976452 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of AIDS
Number of subjects: 28
Study 7976452 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of other somatic illness
Number of subjects: 28
Study 7976452 — intervention group
Group type: COMPARATOR
Intervention: Other suicides (control group)
Number of subjects: 28
Study 2722050 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraperitoneal selective paraaortic lymphadenectomy (EP-SPAL)
Number of subjects: 284
Study 2722050 — intervention group
Group type: COMPARATOR
Intervention: Transperitoneal selective paraaortic lymphadenectomy (TP-SPAL)
Number of subjects: 284
Study 31322915 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic side wall boost (dose not specified)
Number of subjects: 285
Study 31322915 — intervention group
Group type: COMPARATOR
Intervention: No pelvic side wall boost
Number of subjects: 285
Study 31322915 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose escalated combined external beam with interstitial boost
Number of subjects: 285
Study 29231608 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia combined with EA pretreatment at Zusanli (ST 36), Shangjuxu (ST 37), Xiajuxu (ST 39), Tianshu (ST 25) and Zhongwan (CV 12)
Number of subjects: 60
Study 29231608 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anesthesia
Number of subjects: 60
Study 29231608 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia combined with EA pretreatment at Zusanli (ST 36), Shangjuxu (ST 37), Xiajuxu (ST 39)
Number of subjects: 60
Study 26156691 — intervention group
Group type: EXPERIMENTAL
Intervention: B-mode ultrasound-guided percutaneous transhepatic gallbladder drainage (PTGD) + laparoscopic cholecystectomy (LC)
Number of subjects: 35
Study 26156691 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC) alone
Number of subjects: 35
Study 23305460 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 IU/kg of 4-factor prothrombin complex concentrate (PCC)
Number of subjects: 59
Study 23305460 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 IU/kg of 4-factor prothrombin complex concentrate (PCC)
Number of subjects: 59
Study 21467200 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced needle (RN) with a diameter of 0.9 mm for the last 50 mm from the tip
Number of subjects: 257
Study 21467200 — intervention group
Group type: COMPARATOR
Intervention: Standard needle (SN) with a diameter of 1.4 mm
Number of subjects: 257
Study 21467200 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced needle (RN)
Number of subjects: 257
Study 21467200 — intervention group
Group type: COMPARATOR
Intervention: Standard needle (SN)
Number of subjects: 257
Study 18279411 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent physiotherapy (4 times a week for 4 weeks with a 6-week treatment pause, total of 30 weeks)
Number of subjects: 25
Study 18279411 — intervention group
Group type: COMPARATOR
Intervention: Continuous physiotherapy (once or twice a week for a total of 30 weeks)
Number of subjects: 25
Study 16413647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16413647 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatments for OCD
Number of subjects: 0
Study 11914892 — intervention group
Group type: EXPERIMENTAL
Intervention: Technetium-99m ciprofloxacin scan
Number of subjects: 71
Study 11914892 — intervention group
Group type: EXPERIMENTAL
Intervention: Late imaging assessment
Number of subjects: 71
Study 11914892 — intervention group
Group type: COMPARATOR
Intervention: Articular uptake
Number of subjects: 71
Study 10591286 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ecopipam
Number of subjects: 11
Study 10591286 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg ecopipam
Number of subjects: 11
Study 10591286 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ecopipam
Number of subjects: 11
Study 10591286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 9002920 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine swabbing (10 mL 0.12% chlorhexidine gluconate)
Number of subjects: 44
Study 9002920 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine swabbing (10 mL 0.12% chlorhexidine gluconate) with dental prophylaxis
Number of subjects: 44
Study 9002920 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine swabbing at maintenance frequency with periodic dental prophylaxis
Number of subjects: 44
Study 9002920 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine swabbing
Number of subjects: 44
Study 2248068 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 30
Study 2248068 — intervention group
Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 30
Study 6101960 — intervention group
Group type: COMPARATOR
Intervention: pemoline (20 and 40 mg)
Number of subjects: 6
Study 6101960 — intervention group
Group type: COMPARATOR
Intervention: prolintane hydrochloride (5 and 10 mg)
Number of subjects: 6
Study 6101960 — intervention group
Group type: COMPARATOR
Intervention: methylphenidate hydrochloride (10 and 20 mg)
Number of subjects: 6
Study 6101960 — intervention group
Group type: COMPARATOR
Intervention: fencamfamine hydrochloride (10 and 20 mg)
Number of subjects: 6
Study 6101960 — intervention group
Group type: COMPARATOR
Intervention: caffeine anhydrous (100, 200 and 300 mg)
Number of subjects: 6
Study 6462734 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose nitrofurantoin
Number of subjects: 0
Study 31182699 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal Hemorrhoidal Dearterialization (THD)
Number of subjects: 87
Study 31182699 — intervention group
Group type: COMPARATOR
Intervention: Milligan Morgan Hemorrhoidectomy (MM)
Number of subjects: 87
Study 30426700 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm condition (26°C-27°C)
Number of subjects: 25
Study 30426700 — intervention group
Group type: COMPARATOR
Intervention: Control condition (19°C-20°C)
Number of subjects: 25
Study 25921050 — intervention group
Group type: EXPERIMENTAL
Intervention: PR-fampridine
Number of subjects: 132
Study 25921050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 25227824 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on protection motivation theory and implementation intentions
Number of subjects: 200
Study 25227824 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 200
Study 22691567 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline (1000 mg every 12 h intravenously during the first 3 days and orally thereafter for a total of 6 weeks [2×500 mg oral tablets given every 12 h])
Number of subjects: 2298
Study 22691567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2298
Study 19837639 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumination
Number of subjects: 99
Study 19837639 — intervention group
Group type: COMPARATOR
Intervention: Distraction
Number of subjects: 99
Study 17588546 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonergic + Noradrenergic antidepressant drugs (e.g., venlafaxine, duloxetine, milnacipran, mirtazapine, mianserin, moclobemide)
Number of subjects: 17036
Study 17588546 — intervention group
Group type: COMPARATOR
Intervention: Selective Serotonin Reuptake Inhibitors (SSRIs)
Number of subjects: 17036
Study 17588546 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonergic + Noradrenergic antidepressant drugs
Number of subjects: 17036
Study 17588546 — intervention group
Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 17036
Study 16224163 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-guided LASIK
Number of subjects: 57
Study 12063642 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg)
Number of subjects: 24
Study 12063642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10088764 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtration leukocytapheresis (LCP)
Number of subjects: 25
Study 10088764 — intervention group
Group type: COMPARATOR
Intervention: Sham apheresis (control group)
Number of subjects: 25
Study 8776075 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate (400 micrograms per day)
Number of subjects: 95
Study 8776075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 2254558 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose amiodarone, 200 mg/day (Group 2, n = 98)
Number of subjects: 312
Study 2254558 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually treated antiarrhythmic therapy (Group 1, n = 100)
Number of subjects: 312
Study 2254558 — intervention group
Group type: COMPARATOR
Intervention: No antiarrhythmic therapy (Group 3 [control group], n = 114)
Number of subjects: 312
Study 6994772 — intervention group
Group type: EXPERIMENTAL
Intervention: guanfacine 2 mg daily
Number of subjects: 20
Study 6994772 — intervention group
Group type: COMPARATOR
Intervention: placebo preparation
Number of subjects: 20
Study 31610073 — intervention group
Group type: EXPERIMENTAL
Intervention: REDCHiP (video-based telehealth intervention, 10 sessions)
Number of subjects: 42
Study 31610073 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth treatment (after all parents received it)
Number of subjects: 42
Study 31610073 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth treatment (for children who entered treatment above target)
Number of subjects: 42
Study 31610073 — intervention group
Group type: COMPARATOR
Intervention: WAITLIST (usual care)
Number of subjects: 42
Study 31811206 — intervention group
Group type: EXPERIMENTAL
Intervention: Cordimax stent
Number of subjects: 3697
Study 31811206 — intervention group
Group type: COMPARATOR
Intervention: Xience V stent
Number of subjects: 3697
Study 28531363 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrox28
Number of subjects: 108
Study 28531363 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 108
Study 27554184 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective binge eating (OBE)
Number of subjects: 80
Study 27554184 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective binge eating (SBE)
Number of subjects: 80
Study 27554184 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating-related psychopathology and depression symptoms
Number of subjects: 80
Study 27554184 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating-related psychopathology, self-esteem, and anxiety
Number of subjects: 80
Study 27554184 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 80
Study 24498875 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal weight group (BMI 18.5-24.9)
Number of subjects: 30
Study 24498875 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight group (BMI 25.0-29.9)
Number of subjects: 30
Study 24498875 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese group (BMI ≥30.0)
Number of subjects: 30
Study 24498875 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 30
Study 22186099 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 0
Study 22186099 — intervention group
Group type: COMPARATOR
Intervention: Control (non-EPA group)
Number of subjects: 0
Study 20560108 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg once a day plus vildagliptin 50 mg twice a day
Number of subjects: 168
Study 20560108 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride 2 mg 3 times a day plus vildagliptin 50 mg twice a day
Number of subjects: 168
Study 17113192 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweetened vegetable taste during conditioning trials
Number of subjects: 21
Study 17113192 — intervention group
Group type: COMPARATOR
Intervention: Unsweetened vegetable taste at test
Number of subjects: 21
Study 15677780 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive call center support in addition to usual care
Number of subjects: 591
Study 15677780 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 591
Study 14753762 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) training
Number of subjects: 2
Study 14753762 — intervention group
Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 2
Study 14753762 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavity margin angulation
Number of subjects: 2
Study 10361530 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice to lower fat intake with decreased eating frequency
Number of subjects: 80
Study 10361530 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice to lower fat intake with maintained eating frequency
Number of subjects: 80
Study 10361530 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice to maintain fat intake with decreased eating frequency
Number of subjects: 80
Study 10361530 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice to maintain fat intake with increased eating frequency
Number of subjects: 80
Study 7676401 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperlipidemia (defined by serum total cholesterol and triglyceride levels)
Number of subjects: 59
Study 7676401 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiopathic DVT patients
Number of subjects: 59
Study 7676401 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 59
Study 1693055 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour infusion of vancomycin (1.0 g)
Number of subjects: 10
Study 1693055 — intervention group
Group type: COMPARATOR
Intervention: 2-hour infusion of vancomycin (1.0 g)
Number of subjects: 10
Study 6112564 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 214
Study 6112564 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 214
Study 6112564 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin and Atenolol combined
Number of subjects: 214
Study 6112564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 31430313 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention with personalized feedback on AUDIT results
Number of subjects: 560
Study 31430313 — intervention group
Group type: COMPARATOR
Intervention: Health education leaflet (received by both groups)
Number of subjects: 560
Study 31430313 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 560
Study 31430313 — intervention group
Group type: COMPARATOR
Intervention: Both groups (intervention and control)
Number of subjects: 560
Study 30386340 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation (AHSCT)
Number of subjects: 0
Study 30386340 — intervention group
Group type: COMPARATOR
Intervention: Monthly cyclophosphamide
Number of subjects: 0
Study 26459008 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction using a kaleidoscope during venipuncture
Number of subjects: 144
Study 26459008 — intervention group
Group type: COMPARATOR
Intervention: Control group (no distraction) during venipuncture
Number of subjects: 144
Study 24556154 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol administration after 3-hour smoking deprivation
Number of subjects: 128
Study 24556154 — intervention group
Group type: COMPARATOR
Intervention: Alcohol administration after overnight smoking deprivation
Number of subjects: 128
Study 23158941 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong intervention (specific exercises developed by the Heidelberg School of Chinese Medicine)
Number of subjects: 8
Study 23158941 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong intervention
Number of subjects: 8
Study 23158941 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 8
Study 19825948 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib 175 to 1,800 mg once daily
Number of subjects: 81
Study 19825948 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib 500 to 900 mg twice daily
Number of subjects: 81
Study 19825948 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (any dosing)
Number of subjects: 81
Study 17982547 — intervention group
Group type: COMPARATOR
Intervention: No preflaring of the cervical and middle root canal thirds (Group 1)
Number of subjects: 40